Faculty of Medicine, Department of Clinical Sciences, Lund University, SE-205 02 Malmö, Sweden.
Acta Derm Venereol. 2013 Jan;93(1):50-6. doi: 10.2340/00015555-1409.
Persistent, itching nodules have been reported to appear at the injection site after allergen-specific immuno-therapy with aluminium-precipitated antigen extract, occasionally in conjunction with contact allergy to aluminium. This study aimed to quantify the development of contact allergy to aluminium during allergen-specific immunotherapy. A randomized, controlled, single-blind multicentre study of children and adults entering allergen-specific immunotherapy was performed using questionnaires and patch-testing. A total of 205 individuals completed the study. In the 3 study groups all subjects tested negative to aluminium before allergen-specific immunotherapy and 4 tested positive after therapy. In the control group 4 participants tested positive to aluminium. Six out of 8 who tested positive also had atopic dermatitis. Positive test results were found in 5/78 children and 3/127 adults. Allergen-specific immunotherapy was not shown to be a risk factor for contact allergy to aluminium. Among those who did develop aluminium allergy, children and those with atopic dermatitis were more highly represented.
有报道称，在使用铝沉淀抗原提取物进行过敏原特异性免疫治疗后，注射部位会出现持续瘙痒的结节，偶尔伴有对铝的接触过敏。本研究旨在定量评估过敏原特异性免疫治疗过程中对铝的接触过敏的发展情况。采用问卷调查和斑贴试验，对接受过敏原特异性免疫治疗的儿童和成人进行了一项随机、对照、单盲多中心研究。共有 205 人完成了这项研究。在这 3 个研究组中，所有受试者在过敏原特异性免疫治疗前均对铝呈阴性反应，4 人在治疗后呈阳性反应。在对照组中，4 名参与者对铝呈阳性反应。其中 6 名呈阳性反应的人也患有特应性皮炎。78 名儿童中有 5 名和 127 名成人中有 3 名的测试结果呈阳性。过敏原特异性免疫治疗并不是导致对铝接触过敏的危险因素。在那些确实发生铝过敏的人群中，儿童和特应性皮炎患者的比例更高。
